Obesity research & clinical practice · 2025
Is single anastomosis duodenoileal bypass (SADI) an effective option for conversional surgery following sleeve gastrectomy? A comprehensive review and revised scope of current literature.
СтатьяСистематический обзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Pereira Ana Marta, Pereira Sofia S, Monteiro Mariana P, Guimarães Marta
Аннотация
BACKGROUND: Conversional surgery following sleeve gastrectomy (SG) is required in about 20 % of patients due to suboptimal outcomes. Single anastomosis duodenoileal bypass (SADI) has emerged as an option for such cases, though long-term outcomes remain unclear. This review analyzed available data on SADI as a conversional or second-stage procedure after SG.
METHODS: A systematic search across PubMed, Web of Science, and Scopus included studies on adult patients who underwent SADI as a conversional or second-stage surgery following SG, with a minimum of 12 months' follow-up up to July 2024.
RESULTS: Nineteen studies involving 867 patients examined weight loss, comorbidity resolution, postoperative complications, and nutritional deficiencies. Results showed a total weight loss (TWL) of 24 % in the first year post-revision, with a trend toward weight stabilization or regain over two years. Maximum TWL (27 %) occurred at 24 months, decreasing to 24 % at 60 months. Average follow-up of 27 months showed remission rates for type 2 diabetes, hypertension, and dyslipidemia at 68 %, 53 %, and 37 %, respectively. Short-term morbidity within 30 days was 8 %, including a 5 % rate of anastomotic leaks or fistulas and a 5 % reoperation rate. Overall mortality was 2 %.
CONCLUSION: In conclusion, SADI shows promise as a safe and effective mid-term conversional surgery after SG with suboptimal results. However, further studies are needed to confirm its long-term safety and effectiveness.
METHODS: A systematic search across PubMed, Web of Science, and Scopus included studies on adult patients who underwent SADI as a conversional or second-stage surgery following SG, with a minimum of 12 months' follow-up up to July 2024.
RESULTS: Nineteen studies involving 867 patients examined weight loss, comorbidity resolution, postoperative complications, and nutritional deficiencies. Results showed a total weight loss (TWL) of 24 % in the first year post-revision, with a trend toward weight stabilization or regain over two years. Maximum TWL (27 %) occurred at 24 months, decreasing to 24 % at 60 months. Average follow-up of 27 months showed remission rates for type 2 diabetes, hypertension, and dyslipidemia at 68 %, 53 %, and 37 %, respectively. Short-term morbidity within 30 days was 8 %, including a 5 % rate of anastomotic leaks or fistulas and a 5 % reoperation rate. Overall mortality was 2 %.
CONCLUSION: In conclusion, SADI shows promise as a safe and effective mid-term conversional surgery after SG with suboptimal results. However, further studies are needed to confirm its long-term safety and effectiveness.